[Therapy of a hypereosinophilic syndrome with cardiac involvement].
The case of a young patient suffering from a hypereosinophilic syndrome (HES), complicated by restrictive cardiomyopathy and severe mitral regurgitation is analyzed, according to clinical, echocardiographic, haemodynamic, and bioptic histological findings. Seven days after mitral valve replacement (St. Jude Medical valve), the patient died in cardiogenic shock. The present state of treatment of this disease is discussed.
Wildhagen
K
K
Zentrum Innere Medizin und Dermatologie der Medizinischen Hochschule Hannover, Abt. Immunologie.
Buhr-Wildhagen
S
S
Reil
G H
GH
Lichtlen
P R
PR
D000328:Adult; D002313:Cardiomyopathy, Restrictive / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D004699:Endocardium / Q000473:pathology; D004802:Eosinophilia / Q000473:pathology / Q000628:therapy*; D006350:Heart Valve Prosthesis; D006801:Humans; D008297:Male; D008943:Mitral Valve / Q000473:pathology; D008944:Mitral Valve Insufficiency / Q000473:pathology / Q000628:therapy*; D009206:Myocardium / Q000473:pathology; D011183:Postoperative Complications / Q000473:pathology; D011379:Prognosis
Uberlegungen zur Therapie bei hypereosinophilem Syndrom mit kardialer Beteiligung.